Drug Sponsors

Geron discontinues GRN100, cuts 43 workers

Wednesday, December 5, 2012 11:08 AM

Geron, a Menlo Park, Calif.-based biopharmaceutical company developing first-in-class therapies for cancer, has discontinued development of GRN1005, its peptide-drug conjugate designed to treat cancers in the brain. Going forward, the company will focus on the development of imetelstat, its telomerase inhibitor, in hematologic myeloid malignancies and in patients with solid tumors that have short telomeres.

More... »

Baxter to acquire Gambro, enhance renal therapies portfolio

Wednesday, December 5, 2012 10:40 AM

Baxter International, a global healthcare company, has entered into a definitive agreement to acquire Gambro, a privately held dialysis product company based in Lund, Sweden, for total consideration of approximately $4 billion.

More... »

NextPharma completes sale of U.S. affiliate

Monday, December 3, 2012 12:44 PM

NextPharma Technologies Holding, a contract manufacturer in Europe, has completed the sale of Bioserv, its U.S. affiliate based in San Diego, to KESA Partners.

More... »

Volcano to acquire Crux Biomedical

Monday, December 3, 2012 11:21 AM

Volcano, a developer and manufacturer of precision guided therapy tools for treatment of coronary and peripheral vascular disease, has signed an agreement to acquire Crux Biomedical, a privately-held company that has developed a highly differentiated inferior vena cava (IVC) filter—the Crux VCF System—to treat pulmonary embolisms (PE's).

More... »

BioCryst, Presidio mutually terminate merger

Friday, November 30, 2012 01:50 PM

BioCryst Pharmaceuticals, a biopharmaceutical company focused on infectious and inflammatory diseases, and privately held Presidio Pharmaceuticals, a San Francisco-based clinical stage specialty pharmaceutical company focused on small molecule antiviral therapeutics, have agreed to the mutual termination of their Merger Agreement and the related Investor Financing Agreement entered into on October 17, 2012.

More... »

Rib-X Pharmaceuticals closes first tranche in $67.5M financing

Friday, November 30, 2012 10:28 AM

Rib-X Pharmaceuticals, a New Haven, Conn.-based biopharmaceutical company developing new antibiotics to treat serious and life-threatening infections, has closed the first tranche of a $67.5 million Series 2 preferred stock financing. A second tranche is anticipated to close around the end of 2012.

More... »

Pfizer acquires NextWave Pharmaceuticals

Thursday, November 29, 2012 01:49 PM

Pfizer has completed its acquisition of NextWave Pharmaceuticals, a privately held, specialty pharmaceutical company focused on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD).

More... »

Abbott board approves separation of AbbVie

Thursday, November 29, 2012 01:46 PM

The board of directors of Illinois-based Abbott has approved the separation of its research-based pharmaceuticals business, to be known as AbbVie, and declared a special dividend distribution of all outstanding shares of AbbVie common stock.

More... »

Rhythm expands Series B financing to $33M with Pfizer investment

Wednesday, November 28, 2012 10:48 AM

Rhythm, a Boston-based biotechnology company developing peptide therapeutics that for metabolic diseases, has raised an additional $8 million to complete a $33 million Series B financing.

More... »

Merit Medical to acquire Thomas Medical for $167M

Wednesday, November 28, 2012 10:19 AM

Merit Medical Systems, a manufacturer and marketer of proprietary disposable devices used primarily in cardiology, radiology and endoscopy, has entered into a stock purchase agreement to acquire Thomas Medical Products from GE Healthcare in a $167 million all-cash transaction, subject to customary post-closing adjustments.

More... »